July 30, 2019 08:48 AM EDTUpdated 09:44 AM
R&D

The patent play: Bio­gen gets a PhI­II boost for its bit-bet­ter take on the block­buster MS fran­chise drug Tec­fidera

John Carroll

Editor & Founder

Bio­gen $BI­IB got some mod­est­ly up­beat news from the R&D group to­day on a suc­ces­sor drug to Tec­fidera, their big mul­ti­ple scle­ro­sis fran­chise ther­a­py. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times